Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
about
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumorsSafety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancerRole of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsPhase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application.A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.Metabolically programmed iron chelatorsSimultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray IonisationModulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerA phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Automatic Supported Liquid Extraction (SLE) Coupled with HILIC-MS/MS: An Application to Method Development and Validation of Erlotinib in Human Plasma.Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.Antineoplastic drugs and their analysis: a state of the art review.Therapeutic drug monitoring and tyrosine kinase inhibitors.Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.Nanostructured surfaces for analysis of anticancer drug and cell diagnosis based on electrochemical and SERS tools.Validated Stability-Indicating Chromatographic Method for the Assay of Erlotinib Active Pharmaceutical Ingredient
P2860
Q33732128-A7C08EAA-0881-4F16-8552-29270672353AQ34253761-BB8871E1-DDCA-4C31-9DD3-716CD52045F1Q34398312-A076402C-3E93-451F-AF65-35D02F0ED736Q34472367-592788E2-EB50-49C8-8CB7-ED13388AAF28Q34480582-4E3C85EA-EF58-4AF4-832A-A084BA9DDF47Q34549722-037F23FE-597D-4E99-95DA-85EF7CA996F1Q34578584-57806706-D0F1-49EB-BB3F-4348FAF9C994Q35313647-970B8C8E-664E-4F78-B654-67A2AD35551EQ35836433-3D635761-7FDC-4486-AE72-98622E6BC668Q36080621-1314AAB1-E222-4F88-B94C-002DF441118AQ36170377-5D2104EB-2F60-41E3-AEFE-322B24DDA8D4Q36248997-8661D677-750B-48B7-86AD-7230D97C98DFQ36667508-16368FBC-5EF4-4AE0-864E-EF9DA0D10888Q36713494-F87B7A18-BEDC-4040-81E4-C54404724F57Q37217268-45AB5A50-B9CE-4A34-A249-FE62B39C3911Q37418498-71F3ED61-266A-4641-9A42-FDC915294255Q37539257-53CC2570-8FB5-4637-9098-70162673EB72Q37873453-45C6CF36-ACC0-4526-9F6A-8F53F4BF2F25Q38753340-52658E32-4B12-40CA-B2E3-62C12C692939Q39034201-DF46B21F-A019-4336-9A75-A80E8FEB96ADQ39339684-B01AB996-CC69-491D-833D-E7DEA462DE9AQ41846251-ABAF3625-A2C0-4398-91E0-FA03EBBF43FAQ47842123-23B46731-C0B7-432D-8BE5-1540171B6A9BQ51011218-5B291F77-DF18-46B7-88FA-564C2D125F1CQ53686702-A68FE9C4-0CA6-4717-94AC-CD21A5A1DF8AQ58128351-A69A2258-1ADB-482E-8102-BA7A310DE4FD
P2860
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Specific method for determinat ...... aphy-tandem mass spectrometry.
@en
Specific method for determinat ...... aphy-tandem mass spectrometry.
@nl
type
label
Specific method for determinat ...... aphy-tandem mass spectrometry.
@en
Specific method for determinat ...... aphy-tandem mass spectrometry.
@nl
prefLabel
Specific method for determinat ...... aphy-tandem mass spectrometry.
@en
Specific method for determinat ...... aphy-tandem mass spectrometry.
@nl
P2093
P1476
Specific method for determinat ...... aphy-tandem mass spectrometry.
@en
P2093
Michelle A Rudek
Sharyn D Baker
P304
P356
10.1016/S1570-0232(03)00356-8
P577
2003-08-01T00:00:00Z